Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing

被引：21
作者：
Abelson, Mark B. [1 ]
Gomes, Paul J. [1 ]
机构：
[1] Schepens Eye Res Inst, Boston, MA USA
来源：
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2008年 / 4卷 / 04期
关键词：
antiallergy; antihistamine; olopatadine; ophthalmic;
D O I：
10.1517/17425255.4.4.453
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: Olopatadine 0.2% is the first topical ophthalmic antihistamine/mast cell stabilizer indicated for once-daily dosing. Objective: This review provides a comprehensive description of the pharmacology of the olopatadine molecule, as well as of the clinical efficacy, tolerability, and safety of olopatadine 0.2% ophthalmic solution. Methods: References cited in this review were obtained from the PubMed biomedical literature database. Also included were several posters presented at nationally renowned ophthalmology-related conferences. Results/conclusion: Olopatadine 0.2% was found to be a safe and effective medication for the reduction of itching with a duration of action of up to 24 h. The added convenience of a once-a-day dosing regimen is a major advancement in this drug class.
引用
收藏
页码：453 / 461
页数：9
相关论文
共 62 条
[1]   Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis [J].
Abelson, Mark B. ;
Gornes, Paul J. ;
Pasquine, Terri ;
Edwards, Michael R. ;
Gross, Robert D. ;
Robertson, Stella M. .
ALLERGY AND ASTHMA PROCEEDINGS, 2007, 28 (04) :427-433
[2]  
Abelson Mark B, 2003, Ocul Surf, V1, P127
[3]   Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model [J].
Abelson, MB .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (03) :211-218
[4]   Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis [J].
Abelson, MB ;
Gomes, PJ ;
Vogelson, CT ;
Pasquine, TA ;
Turner, FD ;
Wells, DT ;
Robertson, SM .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (05) :683-691
[5]   Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model [J].
Abelson, MB ;
Greiner, JV .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) :1953-1958
[6]   Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: A randomized, double-masked environmental study [J].
Abelson, MB ;
Gomes, PJ ;
Vogelson, CT ;
Pasquine, TA ;
Gross, RD ;
Turner, FD ;
Wells, DT ;
Bergamini, MVW ;
Robertson, SM .
CLINICAL THERAPEUTICS, 2004, 26 (08) :1237-1248
[7]  
Abelson MB, 2003, CLIN THER, V25, P2070
[8]   CONJUNCTIVAL ALLERGEN CHALLENGE - A CLINICAL APPROACH TO STUDYING ALLERGIC CONJUNCTIVITIS [J].
ABELSON, MB ;
CHAMBERS, WA ;
SMITH, LM .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (01) :84-88
[9]   An evaluation of onset and duration of action of Patanol® (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin® (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model [J].
Abelson, MB ;
Welch, DL .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 :60-63
[10]   Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity [J].
Abelson, MB ;
Spitalny, L .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 125 (06) :797-804
1234567